Inaxaplin
CAS No. 2446816-88-0
Inaxaplin ( VX-147 )
Catalog No. M28276 CAS No. 2446816-88-0
Inaxaplin is an apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 372 | Get Quote |
|
5MG | 620 | Get Quote |
|
10MG | 881 | Get Quote |
|
25MG | 1314 | Get Quote |
|
50MG | 1764 | Get Quote |
|
100MG | 2385 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameInaxaplin
-
NoteResearch use only, not for human use.
-
Brief DescriptionInaxaplin is an apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
-
DescriptionInaxaplin is an apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.(In Vitro):Inaxaplin is an apolipoprotein L1 function inhibitor.
-
SynonymsVX-147
-
PathwayOthers
-
TargetOther Targets
-
Recptor14-3-3 protein-protein interaction
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2446816-88-0
-
Formula Weight417.4
-
Molecular FormulaC21H18F3N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mancini M, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604.
molnova catalog
related products
-
(+)-Puerol B 2-O-glu...
(+)-Puerol B 2''-O-glucoside is a natural product for research related to life sciences.
-
Bacopaside X
Bacopaside X (9.06 μM) showed binding affinity towards the D1 receptor.
-
Ethyl oleate
Ethyl oleate is the liquid lipid component in nanostructured lipid carriers (NLCs).?NLC is a promising vehicle for oral trans-Ferulic acid (TFA) administration.?